Bank of New York Mellon
GMAB icon

Bank of New York Mellon’s Genmab GMAB Stock Holding History

Bank of New York Mellon’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
60,106
+1,185
+2% +$31.5K ﹤0.01% 3065
2026
Q1 		$1.58M Buy
58,921
+2,442
+4% +$73.2K ﹤0.01% 2942
2025
Q4 		$1.74M Buy
56,479
+1,205
+2% +$37.6K ﹤0.01% 2917
2025
Q3 		$1.7M Sell
55,274
-928
-2% -$22.6K ﹤0.01% 2903
2025
Q2 		$1.16M Buy
56,202
+2,653
+5% +$54.5K ﹤0.01% 3057
2025
Q1 		$1.05M Sell
53,549
-18,074
-25% -$379K ﹤0.01% 3039
2024
Q4 		$1.49M Buy
71,623
+2,749
+4% +$60.4K ﹤0.01% 2896
2024
Q3 		$1.68M Sell
68,874
-1,297
-2% -$34.7K ﹤0.01% 2842
2024
Q2 		$1.76M Buy
70,171
+3,283
+5% +$93.1K ﹤0.01% 2865
2024
Q1 		$2M Sell
66,888
-2,723
-4% -$80K ﹤0.01% 2763
2023
Q4 		$2.22M Sell
69,611
-16,376
-19% -$514K ﹤0.01% 2778
2023
Q3 		$3.03M Sell
85,987
-12,260
-12% -$467K ﹤0.01% 2570
2023
Q2 		$3.73M Sell
98,247
-7,593
-7% -$303K ﹤0.01% 2482
2023
Q1 		$4M Sell
105,840
-3,961
-4% -$152K ﹤0.01% 2418
2022
Q4 		$4.65M Sell
109,801
-17,244
-14% -$711K ﹤0.01% 2379
2022
Q3 		$4.08M Sell
127,045
-8,588
-6% -$302K ﹤0.01% 2400
2022
Q2 		$4.41M Buy
135,633
+18,786
+16% +$609K ﹤0.01% 2386
2022
Q1 		$4.23M Buy
116,847
+4,665
+4% +$160K ﹤0.01% 2511
2021
Q4 		$4.44M Buy
112,182
+1,484
+1% +$61.9K ﹤0.01% 2527
2021
Q3 		$4.84M Buy
110,698
+35,195
+47% +$1.58M ﹤0.01% 2506
2021
Q2 		$3.08M Sell
75,503
-619
-0.8% -$23.9K ﹤0.01% 2739
2021
Q1 		$2.5M Sell
76,122
-2,213
-3% -$83.2K ﹤0.01% 2797
2020
Q4 		$3.19M Buy
78,335
+102
+0.1% +$3.81K ﹤0.01% 2578
2020
Q3 		$2.87M Sell
78,233
-12,502
-14% -$452K ﹤0.01% 2479
2020
Q2 		$3.08M Buy
90,735
+6,079
+7% +$166K ﹤0.01% 2451
2020
Q1 		$1.79M Sell
84,656
-5,697
-6% -$127K ﹤0.01% 2609
2019
Q4 		$2.02M Sell
90,353
-876
-1% -$19.1K ﹤0.01% 2814
2019
Q3 		$1.85M Buy
+91,229
New +$1.8M ﹤0.01% 2792

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of New York Mellon's GMAB Position: Q2 2026 in Review

Bank of New York Mellon increased its Genmab (GMAB) stake by 2% in Q2 2026, buying an estimated $31.5K and bringing the position to 60,106 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Bank of New York Mellon first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $4.84M in Q3 2021. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Bank of New York Mellon held 60,106 shares of Genmab worth $1.65M as of Q2 2026.
  • Bank of New York Mellon bought 1,185 Genmab shares in Q2 2026, an estimated $31.5K.
  • Genmab made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3065 holding.
  • Bank of New York Mellon first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Bank of New York Mellon's Genmab position peaked at $4.84M in Q3 2021.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.